Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression. Nevertheless, how tafamidis alters clinical and imaging parameters remains unclear.
Objectives: This systemic review and meta-analysis aimed to investigate how tafamidis remodels the myocardium and influences the disease trajectory of ATTR-CM.
Methods: PubMed, EMBASE, and the Cochrane Library were searched for literature from inception to February 2024 which reported either the effects of tafamidis treatment or natural course of ATTR-CM. Outcomes of interests were all clinical and imaging parameters available from at least 2 independent studies.
Results: We identified 30 studies comprising 2,973 participants with ATTR-CM. Pooling all studies with outcomes of both tafamidis and placebo, tafamidis significantly reduced all-cause mortality (OR: 0.19; 95% CI: 0.07 to 0.56) and cardiovascular death (OR: 0.08; 95% CI: 0.02-0.30). Tafamidis also ameliorated the deterioration of 6-minute walk distance (standardized mean difference [SMD] 0.04 vs. -0.29, P = 0.002) and serum N-terminal pro-B-type natriuretic peptide level (SMD: -0.03 vs 0.41, P < 0.001). Regarding imaging parameters, better global longitudinal strain on echocardiography (SMD: 0.06 vs 0.50, P = 0.003), heart to contralateral ratio (SMD: -0.23 vs. -1.17, P = 0.037) on technetium-99m pyrophosphate scintigraphy, extracellular volume (P = 0.003), left (P < 0.001) and right (P = 0.001) ventricular ejection fraction, and right atrium area (P = 0.033) on cardiac magnetic resonance imaging were observed after tafamidis treatment.
Conclusions: Tafamidis improves clinical outcomes and limits the progression of cardiac remodeling in ATTR-CM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacadv.2024.101511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transthyretin Amyloid Cardiomyopathy: Wherever Protein Stabilization Leads, Disease Stabilization Follows.
J Am Coll Cardiol
March 2025
Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address:
Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis.
Egypt Heart J
March 2025
Padjadjaran University, Bandung, Indonesia.
Background: Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cause of diastolic heart failure associated with poor prognosis. Currently available treatment, tafamidis, a TTR stabilizer, is highly effective and tolerable but is not cost-effective. Hence, we aim to evaluate the efficacy and safety of a mechanistically similar but more affordable TTR stabilizer, diflunisal, in patients with ATTR-CA.
View Article and Find Full Text PDFMyocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment.
Circ Rep
March 2025
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Background: To further elucidate the clinical implications of myocardial T1 mapping with cardiac magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy (ATTR-CM), we investigated the relationships of native myocardial T1 value (T1) and extracellular volume fraction (ECV) with left ventricular (LV) parameters and cardiac biomarkers in ATTR-CM patients before and after tafamidis treatment.
Methods And Results: We studied wild-type ATTR-CM patients who underwent baseline CMR with LV cine and T1 mapping techniques. T1 and ECV were derived from averaged values of base-to-apex LV myocardium.
Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.
Heart Fail Rev
March 2025
Department of Medicine, Texas Tech University Health Science Center, El Paso, TX, USA.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the pathological deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure. While TTR stabilizers such as tafamidis and acoramidis are the only FDA-approved treatments, novel gene-modulating therapies are emerging as transformative approaches. Small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies effectively reduce TTR production and have demonstrated promising clinical outcomes, though their use in cardiac amyloidosis remains investigational.
View Article and Find Full Text PDFATTR Cardiac Amyloidosis in a Patient With Pulmonary Sarcoidosis: Not All That Glitters Is Gold.
JACC Case Rep
March 2025
Division of Cardiology, Department of Medicine, Queen's University, Kingston, Canada. Electronic address:
Background: Amyloid transthyretin (ATTR) cardiac amyloidosis is a progressive cardiomyopathy characterized by misfolded transthyretin deposition, resulting in ventricular stiffening which may cause cardiac dysfunction.
Case Summary: An 86-year-old man with history of pulmonary sarcoidosis presented with progressive dyspnea and emesis. An electrocardiogram demonstrated complete heart block and he underwent permanent pacemaker implantation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!